ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 2, 2017, Pages e100-e101

  Nonomura, Y ^a   Otsuka, A ^a   Ohtsuka, M ^b   Yamamoto, T ^b   Dummer, R ^c   Kabashima, K ^a,d,e  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d AGENCY FOR SCIENCE   (Singapore)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS LIKE 5 PROTEIN; ADAMTS PROTEIN; BIOLOGICAL MARKER; CD3 ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NIVOLUMAB; UNCLASSIFIED DRUG; ADAMTSL5 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE EXACERBATION; EPIDERMIS; HUMAN; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; JAPANESE (PEOPLE); LETTER; LYMPHOCYTIC INFILTRATION; MELANOCYTE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; UPREGULATION; METABOLISM; PSORIASIS;

ADAMTS PROTEINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; PSORIASIS; UP-REGULATION;

EID: 84989267367     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13818     Document Type: Letter

References (6)

1. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.
2. Kim SM, Bhonsle L, Besgen P et al. Analysis of the paired TCR alpha- and beta-chains of single human T cells. PLoS ONE 2012; 7: e37338.
3. Arakawa A, Siewert K, Stohr J et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015; 212: 2203–2212.
4. Ohtsuka M, Miura T, Mori T et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015; 151: 797–799.
5. Matsumura N, Ohtsuka M, Kikuchi N et al. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016; 96: 259–260.
6. Kato Y, Otsuka A, Miyachi Y et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. DOI: 10.1111/jdv.13336.